联合吸入舒利迭和思力华治疗稳定期慢性阻塞性肺疾病的疗效观察  

Efficacy of Salmeterol/Fluticasone Propionate(Seretide) and Tiotropium Inhalation Capsules in Patients with Stable COPD

作　　者：付旭明[1] 

机构地区：[1]辽宁省鞍山市第三医院呼吸科,辽宁鞍山114031

出　　处：《中国医药指南》2014年第5期33-34,共2页Guide of China Medicine

摘　　要：目的分析研究舒利迭联合思力华吸入治疗稳定期慢性阻塞性肺疾病的临床疗效和安全性。方法将82例稳定期COPD患者随机分成两组,治疗组41例,吸入舒利迭50μg/250μg,每日2次,间隔12 h。吸入思力华18μg,每日1次。对照组仅吸入舒利迭50μg/250μg,每日2次,间隔12 h。治疗12周后判定疗效。结果共有77例患者完成本实验,治疗组在临床症状体征改善、动脉血气改善及肺功能的改善方面明显优于对照组(P<0.05),用药过程中未出现严重不良反应。结论联合吸入舒利迭和思力华治疗稳定期COPD患者,效果优于单用舒利迭,可以明显改善临床症状及肺功能。Objective To study the efifcacy of salmeterol/lfuticasone propionate（Seretide） and tiotropium inhalation capsules in patients with stable chronic obstructive pulmonary disease（COPD）. Methods 82 patients with stable COPD were randomly divided into 2 groups. 38 patients in treatment group（seretide＋tiotropium）, They were given Seretide（250μg/50μg） inhaling twice daily and tiotropium bromide（18μg） inhaling once daily. 38 patients in control group, They were given Seretide（250μg/50μg） inhaling twice daily. The treatment was last for 12 weeks. Before and after the cause of treatment,Arterial blood gas and lung function of the two groups were examined and compared respectively. Results 82 patients completed the study. The improvement of effective rate,arterial blood gas and lung function in treatment group were better than the control group. No adverse reaction during treatment. Conclusion The combination of seretide and tiotropium can obviously improve clinical symptoms and lung function of the patients with stable COPD. The effects of combination of seretide and tiotropium is better than only seretide.

关 键 词：阻塞性肺疾病 舒利迭 思力华 吸入疗法 

分 类 号：R563.8[医药卫生—呼吸系统]